Background:
Theranostic is a new field of medicine that combines diagnosis and patient-specific targeted
treatment. In the theranostic approach, it is aimed to detect diseased cells by using targeted molecules using
disease-specific biological pathways and then destroy them by cellular irradiation without damaging other
tissues. Diagnostic tests guide the use of specific therapeutic agents by demonstrating the presence of the
receptor/molecule on the target tissue. Because the therapeutic agent is administered to patients who have a
positive diagnostic test, the efficacy of treatment in these patients is largely guaranteed. As therapeutic efficacy
can be predicted by therapeutic agents, it is also possible to monitor the response to treatment. Many diagnostic
and therapeutic procedures in nuclear medicine are classified as theranostic. 131I treatment and scintigraphy is the
best example of theranostic application. Likewise, 177Lu / 90Y octreotate for neuroendocrine tumors, 177Lu PSMA
for metastatic or treatment-resistant prostate cancer, 90Y SIRT for metastatic liver cancer, and 223Ra for bone
metastasis of prostate cancer are widely used. Also nanoparticles are one of the most rapidly developing subjects
of theranostics. Diagnostic and therapeutic agents that show fluorescent, ultrasonic, magnetic, radioactive,
contrast, pharmacological drug or antibody properties are loaded into the nanoparticle to provide theranostatic
use.
Method:
This article will review general aspects of preclinical models for theranostic research, and present
examples from the literature.
Conclusion:
To achieve successful results in rapidly accelerating personalized treatment research of today, the
first step is to conduct appropriate preclinical studies.
Molecular and Functional Links between Neurodevelopmental Processes and Treatment-Induced Neuroendocrine Plasticity in Prostate Cancer Progression
